5HIAA as a marker for anti-vascular activity

5HIAA as a marker for anti-vascular activity: change in serum 5HIAA in patients with advanced colorectal cancer receiving diclofenac or chemotherapy, and in control subjects without cancer receiving diclofenac

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000459628

Acronym

Hi5

Enrollment

Registered

2005-09-22

Start date

2005-07-04

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Group 1:Patients with advanced colorectal cancer who receive a single dose of diclofenac Group3: patients with advanced colorectal cancer receiving their first dose of chemotherapy

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Metastatic colorectal carcinoma; Histologically confirmed carcinoma of colon or rectum; No previous chemotherapy for metastatic disease. Prior adjuvant treatment allowed; Currently awaiting but not receiving chemotherapy; Over 18 years old; Able to give informed consent.

Exclusion criteria

Current use of NSAID, phenothiazine, monoamine oxidase inhibitors; History of peptic ulcer disease; Intolerance of NSAIDs; Creatinine > 0.15mmol/L; pregnancy; Severe impairment of the gastrointestinal tract that may impair absorption of Diclofenac; Platelet count <50PLUS; 10 age matched control subjects.

Outcome results